Progesterone Phenolic (progesterone) NDC 44911-0047

NDC codes

FDA NDC Directory

Product NDC (as listed)44911-0047Labeler and product segments. Claims need a package NDC.

Product NDC at billing width44911-0047Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
44911-0047-1	44911004701	30 mL in 1 BOTTLE, DROPPER (44911-0047-1)Marketed from Mar 11, 2013

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Progesterone Phenolic
Generic name (nonproprietary): progesterone
Active ingredients: Progesterone — 6 [hp_X]/mL
Dosage form: Liquid
Route: Oral
Labeler: Energique, Inc.
Product type: Over-the-counter drug
Marketing category: Unapproved homeopathic
Marketing start: Mar 11, 2013
Listing expires: Dec 31, 2026
Other FDA classes: Progesterone (Chemical structure)
Identifiers: Product ID 44911-0047_079ad30c-1a0d-475b-8043-62ad1f46fb1dSPL ID 079ad30c-1a0d-475b-8043-62ad1f46fb1dSPL set ID 177c7d38-d133-4e3b-a81e-f6bacd39b147UNII 4G7DS2Q64YUPC 0363113600032
Pharmacologic class: Progesterone

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N444911004701 followed by a unit qualifier and the quantity

Package 44911-0047-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 29, 2024.

Indications (excerpt from the label)

INDICATIONS: May temporarily relieve symptoms associated with reactions to progesterone such as mood swings, painful menses, breast tenderness, headaches, hot flashes, and nervousness.** **Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)